Skip to main content
main-content

Dapagliflozin

News

11-14-2018 | SGLT2 inhibitors | News

Registry study supports SGLT2 inhibitor amputation risk

A registry study in The BMJ finds a small but significant increased risk for amputations in patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors.

11-12-2018 | SGLT2 inhibitors | News

Meta-analysis supports cardioprotective benefits of SGLT2 inhibitors

Sodium-glucose cotransporter 2 inhibitors reduce the risk for heart failure hospitalization and renal disease progression in patients with type 2 diabetes regardless of existing cardiovascular disease, meta-analysis data show.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

Read more

Related topics

Superior

Related

Opinion

01-16-2018 | Type 1 diabetes | Editorial | Article

Sodium-glucose cotransporter-2 inhibitors for type 1 diabetes: Ready for prime time?

Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.

11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

11-04-2016 | Clinical trial | Editorial | Article

My EASD 2016 Highlights: From Paleolithic diets to the artificial pancreas

Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.

In depth

11-16-2018 | Dapagliflozin | Feature | Video

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

11-10-2018 | Dapagliflozin | Feature | Video

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

Journal articles and book chapters

07-23-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

06-09-2018 | Cardiovascular disorders | Review | Article

Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA

Khat DZ, Husain M. Curr Diab Rep 2018; 18: 45. doi: 10.1007/s11892-018-1011-7

06-05-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

image credits